In 2022, Paxton announced an investigation into the pricing of insulin due to its dramatically increased costs over time, targeting not just insulin manufacturers but also entities within the supply chain.
Go Paxton!
Praise The Lord thankyou 🙏
Go Paxton!
Praise The Lord thankyou 🙏